News
TCON
1.960
-2.00%
-0.040
Carnival Surges Over 12%, Here's 75 Biggest Movers From Friday
Gainers USA Truck, Inc. (NASDAQ: USAK) shares climbed 112.6% to close at $31.00 on Friday. DB Schenker and USA Truck announced plans to combine and create premier North American transportation solutions provider.
Benzinga · 4d ago
LGMK, AVYA and WRAP among mid-day movers
Gainers: USA Truck (USAK) +111%. ToughBuilt Industries (TBLT) +58%. Zendesk (ZEN) +29%. Femasys (FEMY) +30%. Chimerix (CMRX) +25%. Wrap Technologies (WRAP) +26%. Moving iMage Technologies (MITQ) +18%. TRACON Pharmaceuticals (TCON) +18%. LogicMark (LGMK) +1...
Seekingalpha · 06/24 16:48
$1.1 Million Bet On TRACON Pharmaceuticals? 4 Penny Stocks Insiders are Buying
U.S. stocks opened sharply higher on Friday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in p...
Benzinga · 06/24 14:50
Anebulo, Tenon top healthcare gainers; BioSig, Rigel lead losers' pack
Gainers: Anebulo Pharmaceuticals (ANEB) +32%. Tenon Medical (TNON) +19%. PolarityTE (PTE) +14%. TRACON Pharmaceuticals (TCON) +14%. Bausch Health (BHC) +13%. Losers: BioSig Technologies (BSGM) -26%. Rigel Pharmaceuticals (RIGL) -8%. Valneva (VALN) -8%. Mer...
Seekingalpha · 06/24 14:05
BRIEF-Tracon Pharmaceuticals Entered Into Purchase Agreement With Opaleye L.P.
BRIEF-Tracon Pharmaceuticals Entered Into Purchase Agreement With Opaleye L.P.
Reuters · 06/21 13:25
BRIEF-TRACON Pharmaceuticals Inc Says On June 2 ICC Informed Co Of Extended Time Limit For Tribunal To Render Final Decision In Ongoing Arbitration With I-Mab Until Sept 30
reuters.com · 06/15 12:30
TRACON Pharmaceuticals to Present at the Jefferies Healthcare Conference
SAN DIEGO, June 02, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-indepe...
GlobeNewswire · 06/02 12:05
Eucure Biopharma To Present Clinical Data From YH003 (anti-CD40 mAb) And YH001 (anti-CTLA-4 mAb) Trials At 2022 American Society Of Clinical Oncology (ASCO) Annual Meeting. BZ NOTE: TRACON Entered Into Agreement For Development Of YH001
Eucure Biopharma, a wholly owned subsidiary of Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen"), today announced that it will present two posters at the 2022 ASCO Annual Meeting, taking place
Benzinga · 05/24 12:23
TRACON Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference
SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-indepen...
GlobeNewswire · 05/16 12:05
Recap: TRACON Pharma Q1 Earnings
TRACON Pharma (NASDAQ:TCON) reported its Q1 earnings results on Wednesday, May 11, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings TRACON Pharma missed estimated earnings by 14.29%, reporting an EPS of $-0.48 versus an...
Benzinga · 05/11 21:24
BRIEF-TRACON Expects Current Cash And Cash Equivalents Will Fund Operations Into 2023
reuters.com · 05/11 20:50
TRACON Pharmaceuticals Q1 EPS $(0.48) Misses $(0.42) Estimate
TRACON Pharmaceuticals (NASDAQ:TCON) reported quarterly losses of $(0.48) per share which missed the analyst consensus estimate of $(0.42) by 14.29 percent. This is a 45.45 percent decrease over losses of $(0.33) per
Benzinga · 05/11 20:03
The Daily Biotech Pulse: Veru Shares Up On COVID Candidate Update, FDA Approves Lilly's COVID Treatment, Latest On Sanofi-AstraZeneca RSV Vaccine
Here's a roundup of top developments in the biotech space over the last 24 hours:
Benzinga · 05/11 13:37
Tracon Q1 2022 Earnings Preview
Tracon (NASDAQ:TCON) is scheduled to announce Q1 earnings results on Wednesday, May 11th, after market close. The consensus EPS Estimate is -$0.42 Over the last 3 months, EPS estimates have
Seekingalpha · 05/10 21:35
A Preview Of TRACON Pharmaceuticals's Earnings
TRACON Pharmaceuticals (NASDAQ:TCON) is set to give its latest quarterly earnings report on Wednesday, 2022-05-11. Here's what investors need to know before the announcement. Analysts estimate that TRACON Pharmaceuticals will report an earnings per share (...
Benzinga · 05/10 15:07
TRACON to Report First Quarter 2022 Financial Results and Corporate Update on May 11, 2022
SAN DIEGO, May 04, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-indepen...
GlobeNewswire · 05/04 12:05
4 Stocks Under $3 Insiders Are Aggressively Buying
Gold futures traded slightly higher on Tuesday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested i...
Benzinga · 05/03 14:07
TRACON Pharma says amended protocol for ENVASARC trial approved at all 30 clinical sites
TRACON Pharmaceuticals (NASDAQ:TCON) on Tuesday said the amended protocol to its ENVASARC trial as approved by the U.S. Food and Drug Administration (FDA) in February has been accepted at all
Seekingalpha · 04/19 13:43
BRIEF-Tracon Announces Amended Envasarc Protocol Approved, Open At 30 Clinical Sites
reuters.com · 04/19 12:27
TRACON Pharma Reports Its Amended ENVASARC Protocol Was Approved, Is Open To All 30 Clinical Sites In US, UK
Expects to Report Results of Independent Data Monitoring Committee (IDMC) Mandated Interim Safety Reviews and Interim Efficacy Review in the Second Half of 2022 SAN DIEGO, April 19, 2022 (GLOBE NEWSWIRE) -- TRACON
Benzinga · 04/19 12:06
More
Webull provides a variety of real-time TCON stock news. You can receive the latest news about Tracon Pharmaceu through multiple platforms. This information may help you make smarter investment decisions.
About TCON
TRACON Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of targeted therapeutics for cancer. The Company's product pipelines consist of Envafolimab (KN035), Methoxyamine (TRC102), TJ004309 and Bispecific Antibodies. KN035 is a single-domain PD-L1 antibody that is administered by subcutaneous injection without the need for an adjuvant. KN035 is in Phase II of clinical trials. TRC102 is a clinical-stage small molecule inhibitor of the DNA base excision repair pathway, which is a pathway that causes resistance to alkylating and antimetabolite chemotherapeutics. TRC102 is in multiple Phase I and Phase II clinical trials. TJ004309 is a humanized antibody against CD73, an ecto-enzyme expressed on stromal cells and tumors that converts extracellular adenosine monophosphate (AMP) to adenosine, which is an immunosuppressive metabolite adenosine.